MiR-145–5p reduced ANG II-induced ACE2 shedding and the inflammatory response in alveolar epithelial cells by targeting ADAM17 and inhibiting the AT1R/ADAM17 pathway
European Journal of Pharmacology · 2024
DOI: 10.1016/j.ejphar.2024.176392 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmacology, 2024. Verfasst von Xu'an Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Beijing Anzhen Hospital, Capital Medical University-Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing,…. Hauptthemen laut MEDLINE: MicroRNAs, Acute Lung Injury, Aortic Dissection. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support.
Abstract (Originalsprache)
The excessive elevation of angiotensin II (ANG II) is closely associated with the occurrence and development of aortic dissection (AD)-related acute lung injury (ALI), through its binding to angiotensin II receptor type I (AT1R). MiR-145-5p is a noncoding RNA that can be involved in a variety of cellular physiopathological processes. Transfection with miR-145-5p was found to downregulated the expression of A disintegrin and metalloprotease 17 (ADAM17) and reduced the levels of angiotensin-converting enzyme 2 (ACE2) in lung tissue, while concurrently increasing plasma ACE2 levels in the AD combined with ALI mice. ADAM17 was proved to be a target of miR-145-5p. Transfection with miR-145-5p decreased the shedding of ACE2 and alleviated the inflammatory response induced by ANG II through targeting ADAM17 and inhibiting the AT1R/ADAM17 pathway in A549 cells. In conclusion, our present study demonstrates the role and mechanism of miR-145-5p in alleviating ANG II-induced acute lung injury, providing a new insight into miRNA therapy for reducing lung injury in patients with aortic dissection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Beijing Anzhen Hospital, Capital Medical University-Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing, China; Department of Anesthesiology, Shanxi Bethune Hospital, Shanxi…
- Department of Anesthesiology, Beijing Anzhen Hospital, Capital Medical University-Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing, China. Electronic address: majun@mail.ccmu.edu.cn.
- Department of Anesthesiology, Beijing Anzhen Hospital, Capital Medical University-Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing, China.
- Department of Anesthesiology, Beijing Anzhen Hospital, Capital Medical University-Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing, China; Department of Anesthesiology, Beijing Chao-yang Hospital, Capi…
Förderung
- National Natural Science Foundation of China
- Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support
Zitieren
APA
Wang, X., Ma, J., Lin, D., Bai, Y., Zhang, D., Jia, X., & Gao, J. (2024). MiR-145–5p reduced ANG II-induced ACE2 shedding and the inflammatory response in alveolar epithelial cells by targeting ADAM17 and inhibiting the AT1R/ADAM17 pathway. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2024.176392
Vancouver
Wang X, Ma J, Lin D, Bai Y, Zhang D, Jia X, et al. MiR-145–5p reduced ANG II-induced ACE2 shedding and the inflammatory response in alveolar epithelial cells by targeting ADAM17 and inhibiting the AT1R/ADAM17 pathway. European Journal of Pharmacology. 2024. doi:10.1016/j.ejphar.2024.176392
BibTeX
@article{Wang2024,
author = {Wang, Xu'an and Ma, Jun and Lin, Duomao and Bai, Yang and Zhang, Dongni and Jia, Xiaotong and Gao, Junwei},
title = {MiR-145–5p reduced ANG II-induced ACE2 shedding and the inflammatory response in alveolar epithelial cells by targeting ADAM17 and inhibiting the AT1R/ADAM17 pathway},
journal = {European Journal of Pharmacology},
year = {2024},
doi = {10.1016/j.ejphar.2024.176392}
}
EUVIMED